Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.

作者: P.M.J. Moonen , L.A.L.M. Kiemeney , J.A. Witjes

DOI: 10.1016/J.EURURO.2005.09.002

关键词:

摘要: Abstract Objective To study the diagnostic efficacy of NMP22 ® BladderChek test and to compare it cytology in detection bladder cancer. Methods We evaluated 106 voided urinary specimens patients with suspicion All urine samples were by test, cytology, sediment culture. The value was according correlation cystoscopic findings and, case tumour, histological findings. A negative result a pTaG1 tumour not considered false-negative this study. results compared cytology. Moreover, combination determined. Results In total, 29 had histologically proven transitional cell carcinoma bladder. detected 40% 15 pTa tumours 83.3% 6 pT1 tumours. Cytology 33.3% 66.6%. 1 CIS lesion group follow-up sensitivity specificity 57.1% (CI 28.8–82.3) 89.8% 79.2–96.2) for 42.9% 17.7–71.7) 93.2% 83.5–98.1) Conclusion has slightly higher without relevant loss specificity. Furthermore is an easy instant result. However, no extra adjunction test.

参考文章(19)
J.M. Fitzpatrick, A.B. West, M.R. Butler, V. Lane, J.D. O’Flynn, Superficial Bladder Tumors (Stage pTa, Grades 1 and 2): The Importance of Recurrence Pattern Following Initial Resection The Journal of Urology. ,vol. 135, pp. 920- 922 ,(1986) , 10.1016/S0022-5347(17)45923-4
Felix M. Brown, URINE CYTOLOGY: Is it Still the Gold Standard for Screening? Urologic Clinics of North America. ,vol. 27, pp. 25- 37 ,(2000) , 10.1016/S0094-0143(05)70231-7
VINATA B. LOKESHWAR, MARK S. SOLOWAY, CURRENT BLADDER TUMOR TESTS: DOES THEIR PROJECTED UTILITY FULFILL CLINICAL NECESSITY? The Journal of Urology. ,vol. 165, pp. 1067- 1077 ,(2001) , 10.1016/S0022-5347(05)66428-2
S. Hautmann, N. Filippow, P. Braun, H. Ellinghausen, M. Friedrich, H. Huland, K. Juenemann, 630The new proteomic-based point-of-care (POC) urine NMP22-bladder.chek® compared to the standard NMP22-elisa urine lab test for bladder cancer detection European Urology Supplements. ,vol. 4, pp. 160- ,(2005) , 10.1016/S1569-9056(05)80634-7
C. Gutierrez, J. Palou, A. Bujons, J.C. Iglesias, B. Juaneda, J. Segarra, J. Salvador, H. Villavicencio, 380 The detection of nuclear matrix protein 22 in the follow up of patients after endovesical treatment with BCG European Urology Supplements. ,vol. 3, pp. 97- ,(2004) , 10.1016/S1569-9056(04)90379-X
Mark S. Soloway, Joseph V. Briggman, Gennaro A. Carpinito, Gerald W. Chodak, Paul A. Church, Donald L. Lamm, Paul Lange, Edward Messing, Robert M. Pasciak, George B. Reservitz, Daniel B. Rukstalis, Michael F. Sarosdy, Walter M. Stadler, Robert P. Thiel, Cheryl L. Hayden, Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment The Journal of Urology. ,vol. 156, pp. 363- 367 ,(1996) , 10.1016/S0022-5347(01)65851-8
AFINA S. GLAS, DAPHNE ROOS, MARIJE DEUTEKOM, AEILKO H. ZWINDERMAN, PATRICK M.M. BOSSUYT, KARL H. KURTH, Tumor markers in the diagnosis of primary bladder cancer. A systematic review. The Journal of Urology. ,vol. 169, pp. 1975- 1982 ,(2003) , 10.1097/01.JU.0000067461.30468.6D
NECMETTIN ATSÜ, SINAN EKICI, ÖMER ÖGE, ALI ERGEN, GÜLŞEN HASÇELIK, HALUK ÖZEN, FALSE-POSITIVE RESULTS OF THE NMP22 TEST DUE TO HEMATURIA The Journal of Urology. ,vol. 167, pp. 555- 558 ,(2002) , 10.1016/S0022-5347(01)69084-0
Bas W.G. van Rhijn, Henk G. van der Poel, Theo H. van der Kwast, Urine markers for bladder cancer surveillance: a systematic review. European Urology. ,vol. 47, pp. 736- 748 ,(2005) , 10.1016/J.EURURO.2005.03.014